A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer has failed in a late stage trial, the Swiss pharmaceuticals maker said on Wednesday. Interim results from the phase III Skyscraper-01 study did not meet the target of progressionfree survival in patients with high metastatic non-small cell lung cancer, it said. The other primary endpoint of overall survival was found to be "immature" or incomplete, Roche said, adding the study will continue.
